Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists.
Quick Facts
What This Study Found
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, exenatide) show sustained weight loss and acceptable safety profiles across trials lasting 40-120 weeks. GI side effects are the most common adverse events. Obesity should be treated as a chronic condition requiring long-term medication.
Key Numbers
Studies from 2018-2025. Treatment durations 40-120 weeks. Agents: semaglutide, liraglutide, tirzepatide, exenatide. Populations: adults with/without T2D, adolescents with severe obesity. Sustained weight loss. GI side effects most common.
How They Did This
Systematic review of high-quality RCTs evaluating long-term efficacy and safety of GLP-1RAs for obesity (2018-2025). Assessed weight loss, glycemic control, and adverse events.
Why This Research Matters
Compiles the long-term evidence supporting GLP-1RAs for obesity, reinforcing that these drugs maintain efficacy over years and that obesity management is a long-term commitment.
What This Study Doesn't Tell Us
Limited follow-up beyond 2 years. Population diversity in available trials is limited. Real-world generalizability uncertain. Weight regain after cessation not fully characterized across all agents.
Trust & Context
- Original Title:
- Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists.
- Published In:
- Cureus, 17(7), e88334 (2025)
- Authors:
- Shah, Md Yasir, Mohammad, Ahmad, Bashir Ahmed Samejo, Rabia, Rana, Siddharth, Singla, Shivam, Aurangzeb, Raja Irsalan, Tariq, Muhammad M, Zamir, Muhammad Hamza, Farooq, Umer, Aurangzeb, Raja Faizan, Singla, Bhavna, Rehman, Abdur
- Database ID:
- RPEP-13527
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13527APA
Shah, Md Yasir; Mohammad, Ahmad; Bashir Ahmed Samejo, Rabia; Rana, Siddharth; Singla, Shivam; Aurangzeb, Raja Irsalan; Tariq, Muhammad M; Zamir, Muhammad Hamza; Farooq, Umer; Aurangzeb, Raja Faizan; Singla, Bhavna; Rehman, Abdur. (2025). Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists.. Cureus, 17(7), e88334. https://doi.org/10.7759/cureus.88334
MLA
Shah, Md Yasir, et al. "Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists.." Cureus, 2025. https://doi.org/10.7759/cureus.88334
RethinkPeptides
RethinkPeptides Research Database. "Weight Loss That Lasts: Reviewing the Long-Term Impact of GL..." RPEP-13527. Retrieved from https://rethinkpeptides.com/research/shah-2025-weight-loss-that-lasts
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.